Cytarabine plus G-CSF is more effective than cyclophosphamide plus G-CSF as a stem cell mobilization regimen in multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20021XJ" target="_blank" >RIV/61988987:17110/19:A20021XJ - isvavai.cz</a>

Result on the web

<a href="https://www.nature.com/articles/s41409-018-0396-x" target="_blank" >https://www.nature.com/articles/s41409-018-0396-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41409-018-0396-x" target="_blank" >10.1038/s41409-018-0396-x</a>

Result language

angličtina

Original language name

Cytarabine plus G-CSF is more effective than cyclophosphamide plus G-CSF as a stem cell mobilization regimen in multiple myeloma

Original language description

Cyclophosphamide (Cy) plus granulocyte-colony stimulating factor (G-CSF) is currently a standard regimen for hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma (MM). However, cytarabine (AraC) in intermediate doses plus G-CSF seems to have a higher mobilization efficacy. The aim of this study was to retrospectively compare mobilization using AraC and Cy. Thirty consecutive MM patients were mobilized by Cy + G-CSF, and the subsequent 40 patients by AraC + G-CSF. Both groups were comparable. The target yield of 10 x 10(6) CD34+ cells/kg (for tandem and 2 additional transplantations) was achieved in 98% (AraC) and 57% (Cy) of patients (p &lt; 0.0001) by 1.2 and 2.1 apheresis (means), and by single apheresis in 83 and 17% of patients, respectively. AraC mobilization resulted in higher peak concentration of CD34+ cells in blood (median 238.0 vs. 87.9/mu L, p &lt; 0.0001) and higher CD34+ yield (median 28.6 x 10(6) vs. 10.4 x 10(6)/kg, p &lt; 0.0001) compared to Cy mobilization. Toxicities were comparable except for thrombocytopenia gr. 4, observed in 50% of patients after AraC (Cy 7%). In view of these results, we conclude that mobilization with AraC plus G-CSF is very effective with acceptable toxicity and could be considered in MM patients with planned or expected higher numbers of transplantations.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BONE MARROW TRANSPL

ISSN

0268-3369

e-ISSN

1476-5365

Volume of the periodical

54

Issue of the periodical within the volume

7

Country of publishing house

GB - UNITED KINGDOM

Number of pages

1107

Pages from-to

1114-7

UT code for WoS article

000473724200021

EID of the result in the Scopus database

2-s2.0-85056829713